Patents by Inventor Dagmar Pikas

Dagmar Pikas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immobilised biological entities
    Patent number: 11850334
    Abstract: There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: December 26, 2023
    Assignee: Carmeda AB
    Inventors: Dagmar Pikas, Johan Riesenfeld, Karin Leontein, Eva Koch, Stefan Oscarson
  • IMMOBILISED BIOLOGICAL ENTITIES
    Publication number: 20210379253
    Abstract: There is provided inter alia an anticoagulant surface which surface has covalently bound thereto a plurality of fragments of heparin, wherein said fragments consist of 5-18 saccharide units and at least some of said plurality of fragments comprise polysaccharide sequence A, which surface catalyses the inhibition of FIIa and FXa by AT.
    Type: Application
    Filed: October 3, 2019
    Publication date: December 9, 2021
    Inventors: Dagmar Pikas, Johan Riesenfeld, Karin Leontein, Eva Koch, Stefan Oscarson
  • Use of chemically modified heparin derivates in sickle cell disease
    Patent number: 9480702
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE
    Publication number: 20140364369
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Application
    Filed: December 19, 2012
    Publication date: December 11, 2014
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas